The Catalyst

Most Recent Posts

06.01.12 | By Kate Connors

Yesterday, someone brought to my attention a really interesting study in The Journal of Clinical Hypertension. It evaluated how much the prescribing decisions of physicians are influenced by the information provided to them by biopharmaceutical company sales representatives.

06.01.12 | By Preet Bilinski

Today, thanks in part to the work done in biopharmaceutical research and development, there are a record number of Americans surviving cancer: nearly 12 million. Despite this progress, cancer remains the second leading cause of death by disease in the United States, exceeded only by heart disease.

05.31.12 | By Preet Bilinski

Unfortunately, today most of us know someone that has had to battle cancer. On the bright side, more and more people are winning that fight. We've come a long way since signs of cancer were found in the bones of mummies from ancient Egypt, to declaring war on cancer, to approving vaccines for cancer.

05.30.12 | By Greg Lopes

The Los Angeles Times recently ran a provoking story on insurance company coverage of specialty medicines and the increasing share of the cost patient

05.30.12 | By Jon Tripp

The 2012 Pharmaceutical Industry Profile is now available as a free interactive e-book on the popular iTunes Bookstore.

05.29.12 | By Kate Connors

This year, one of the key topics of conversation at our annual meeting was the importance of collaboration among different members of the research ecosystem - and rightly so, as this collaboration

05.23.12 | By Mark Grayson

Today the U.S. Chamber of Commerce released a study that shows the importance of intellectual property to jobs in every state.

05.23.12 | By Kate Connors

This year's reauthorization of the Prescription Drug User Fee Act is a top priority for PhRMA and for our member companies, who recognize the critical importance of providing FDA with the resources it needs to do its incredibly essential job.

The editors at The Catalyst recently asked John P. Clark, Vice President and Chief Security Officer, Pfizer Inc., a few questions about being on the front line in the battle against foreign counterfeit medicines. John provided a snapshot of the risks patients could face if the closed U.S. drug supply system were to open up. I urge you take a close look at all the pictures provided by Pfizer Inc.

[caption id="attachment_2277" align="alignleft" width="150" caption="Growth Platform for Economies Around the World"][/caption]


[caption id="attachment_2269" align="alignleft" width="150" caption="Growing Global Populations of Elderly"][/caption]


[caption id="attachment_2259" align="alignleft" width="150" caption="Sabrina the caregiver"][/caption]

05.11.12 | By Jon Tripp

[caption id="attachment_2183" align="alignleft" width="132" caption="Happy Mother's Day"][/caption]


On Monday, May 14, PhRMA President and CEO John Castellani will participate on a roundtable in Washington entitled: Spending on Health as an Investment: Fiscal Sustainability and Aging Populations. Mr. Castellani will be joined by Dr.